A fortress-balance-sheet cannabis sale-leaseback REIT priced like distress: NLCP pays an 11%+ yield while acting as a leveraged call option on Schedule III and a potential uplisting re-rating.
NewLake Capital Partners, Inc. (NLCP) presents one of the most compelling yet complex investment narratives in the alternative real estate sector as of January 2026. The company stands at the intersection of a high-growth nascent industry—legal cannabis—and the rigorous discipline of triple-net (NNN) lease real estate. This juxtaposition has created a distinct valuation paradox. Despite operating a portfolio with 100% rent collection from its performing tenants, maintaining a balance sheet with zero debt maturities until 2027, and distributing a dividend that yields approximately 11.4%, the equity trades at multiples that typically signal severe financial distress or secular obsolescence.
The analysis that follows suggests that this valuation disconnect is not a reflection of fundamental asset impairment but rather a "regulatory illiquidity discount." Investors are effectively pricing NLCP as a distressed asset due to the lingering federal illegality of its tenants' primary product, which confines the stock to the OTCQX exchange and precludes institutional capital participation. However, the fundamental reality of the business, as evidenced by its 2024 and 2025 financial performance, tells a story of resilience, disciplined capital allocation, and robust cash flow generation.
The fiscal years 2024 and 2025 were characterized by a "capital famine" in the cannabis sector. High interest rates and the delay of the SAFER Banking Act forced operators to retrench, prioritizing cash flow over growth. Against this backdrop, NLCP demonstrated the defensive nature of its business model.
Revenue Durability: For the nine months ended September 30, 2025, revenue totaled $38.7 million, a 3.0% increase year-over-year.
Earnings Quality: Funds From Operations (FFO) grew to $32.3 million, and Adjusted Funds From Operations (AFFO)—the proxy for dividend safety—reached $33.2 million.
Dividend Aristocracy in Waiting: NLCP has established a track record of dividend reliability, declaring a Q4 2025 dividend of $0.43 per share ($1.72 annualized).
Looking forward, 2026 is poised to be a binary year for NLCP, defined largely by external political and regulatory catalysts rather than internal operational shifts.
The Rescheduling Catalyst: The most significant potential value driver is the rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). Initiated by the Biden administration and accelerated by President Trump's Executive Order in December 2025
The Uplisting Opportunity: A successful rescheduling is widely viewed as the "key" to unlocking major exchange listings (NASDAQ or NYSE). Currently, NLCP trades on the OTCQX, which limits custody for major institutional investors. An uplisting would likely trigger a massive re-rating of the stock, compressing the yield from ~11% to a more normalized REIT yield of 7-8%, implying significant capital appreciation.
Credit Migration Management: The company must navigate the ongoing credit stress of its tenants. Specifically, the liquidity issues at AYR Wellness and the receivership of Revolutionary Clinics in Massachusetts
This report categorizes NewLake Capital Partners as a High-Conviction Buy for Income and Speculative Growth. It serves as a "call option" on U.S. federal cannabis reform, paying a double-digit yield while investors wait. The downside protection is provided by the intrinsic liquidation value (NAV) of its industrial real estate assets and its substantial cash position ($23.6 million).
To understand NLCP's value proposition, one must first understand the structural dysfunction of cannabis finance. Because cannabis remains a Schedule I substance federally, federally chartered banks are largely prohibited from accepting cannabis real estate as collateral for commercial mortgages. This leaves operators with a "capital trap": they may have millions of dollars trapped in the equity of their cultivation facilities but cannot access it to fund operations or growth.
NLCP solves this liquidity crisis through the Sale-Leaseback transaction.
The Transaction: NLCP purchases the cultivation facility or dispensary from the cannabis operator for cash (typically at appraised value or a negotiated cap rate).
The Lease: Simultaneously, the operator signs a long-term (15-20 year) lease to rent the facility back from NLCP.
The Triple-Net (NNN) Structure: The lease is structured as "triple-net," meaning the tenant is responsible for paying all property taxes, insurance premiums, and maintenance costs. NLCP's role is purely capital allocation; they do not fix roofs or pay utilities.
Strategic Moat: Because capital is scarce, NLCP commands lease terms that are vastly superior to those found in traditional industrial real estate.
Cap Rates: NLCP acquires properties at cap rates (initial yields) of 12-14%. Compare this to traditional industrial REITs like Prologis (PLD), which acquire at 5-6%.
Escalators: Leases typically include annual rent escalators of 2-3%.
NLCP's portfolio is heavily weighted toward Cultivation and Processing Facilities rather than retail dispensaries. This distinction is critical for risk assessment.
These are large-scale industrial plants, often exceeding 50,000 square feet, equipped with specialized HVAC, lighting, irrigation, and security systems.
Pros: High "stickiness." Once an operator invests millions in outfitting a facility and licensing it with the state, moving is prohibitively expensive. The "switching cost" is enormous, making lease renewal highly probable.
Cons: Asset specificity. If a tenant fails, repurposing a cannabis grow room for general warehousing requires significant capital expenditure (CapEx) to strip out the specialized equipment. Furthermore, finding a new cannabis tenant depends on the state's licensing cap. In unlimited license states, a vacant grow facility has little value. In limited license states (like PA or CT), the facility is highly valuable because it is one of the few places legally permitted to grow.
These are storefronts in high-traffic commercial corridors.
Pros: easier to re-tenant. If a cannabis tenant fails, the building can easily be converted to a Starbucks, urgent care, or bank branch.
Cons: Lower strategic importance to the tenant compared to the cultivation hub. Retail licenses are often easier to move than cultivation licenses.
Strategic Insight: NLCP's focus on limited-license states (such as Pennsylvania, Connecticut, and Ohio) serves as a hedge against the "commoditization" of cannabis real estate. In these markets, the scarcity of the license accrues value to the real estate attached to it.
The business is inextricably linked to the federal regulatory environment.
The most pervasive headwind for NLCP's tenants is Internal Revenue Code Section 280E. Enacted in the 1980s to penalize drug traffickers, 280E forbids businesses trafficking in Schedule I or II substances from deducting ordinary business expenses (rent, payroll, marketing) from their federal taxes. They can only deduct Cost of Goods Sold (COGS).
Impact: Cannabis operators pay effective tax rates of 70% or more. This decimates free cash flow and increases the risk of defaulting on rent.
The Fix: Rescheduling cannabis to Schedule III would render 280E inapplicable. This would immediately improve the rent coverage ratios of NLCP’s tenants. For example, a tenant currently generating $10M in EBITDA might see that jump to $15M simply by the removal of the tax burden, making NLCP's rent payments far more secure.
In a move that surprised many political observers, President Trump issued an Executive Order in December 2025 directing the Attorney General to "expeditiously" complete the rescheduling process.
Currently, NLCP trades on the OTCQX Best Market. While this is a reputable tier of the OTC, it is not a "national exchange."
The Discount: OTC stocks suffer from a liquidity discount. Many brokerage platforms (Robinhood, WeBull) and institutional mandates restrict trading in OTC securities.
The Goal: Uplisting to NASDAQ or NYSE is the "Holy Grail." It would allow inclusion in passive index funds (like the Vanguard Real Estate ETF, VNQ). The buying pressure from index inclusion alone would likely drive the stock price up 30-50%, lowering NLCP's cost of equity and allowing them to return to growth mode by issuing shares to buy new assets.
NLCP has deliberately chosen to partner with large Multi-State Operators (MSOs).
Top Tenants: The portfolio includes industry giants like Curaleaf and Cresco Labs.
Rationale: Large MSOs have diversified revenue streams across multiple states. If regulatory pricing collapses in one state (e.g., Massachusetts), the MSO can subsidize the loss with profits from a protected market (e.g., Ohio). This "portfolio effect" at the tenant level provides a layer of security for NLCP's rent roll.
Risk: The downside is concentration. If a top tenant like AYR Wellness faces enterprise-wide failure, it jeopardizes a significant portion of NLCP's revenue at once.
The financial narrative of 2024-2025 is one of "boring reliability," which, in the volatile cannabis sector, is a high compliment.
Revenue Analysis:
YTD 2025 Revenue: $38.7 million vs. $37.6 million in YTD 2024 (+3.0%).
Q3 2025 Revenue: $12.6 million (Flat YoY).
Driver: The lack of explosive top-line growth is deliberate. Management, led by CEO Anthony Coniglio, refused to issue equity at depressed valuations (below NAV) to fund acquisitions. They effectively chose to "shrink to grow" per-share metrics rather than dilute shareholders.
Interest Income: A small portion of revenue comes from interest on loans ($137k in Q3 2025)
Expense Management:
G&A Efficiency: NLCP operates with a lean team (approx. 8 employees).
Margin Profile: The company boasts EBITDA margins consistently above 85%, reflecting the NNN nature of the leases where the landlord has minimal property-level expenses.
In REIT analysis, Net Income is often misleading due to non-cash depreciation charges. The true measure of cash flow is Adjusted Funds From Operations (AFFO).
Table 3.1: Financial Performance Snapshot (Q3 2025 vs Q3 2024)
Source:
Insight: The growth in AFFO per share despite flat revenue suggests active capital management (likely share repurchases or lower interest expense) and the positive impact of rent escalators.
NLCP's balance sheet is arguably its strongest asset, acting as a fortress against the high-interest-rate environment of 2024-2025.
Gross Assets: $432.2 million in real estate properties.
Cash Position: $23.6 million in cash and equivalents.
Debt Profile: The company has essentially no debt ($2 million on a revolver vs. $432M assets), resulting in a debt-to-asset ratio of just 1.6%.
Liquidity: Total liquidity stands at $106.0 million ($23.6M cash + $82.4M revolver capacity).
Strategic Implication: While peers in the broader real estate sector (office, commercial) are grappling with refinancing walls and soaring interest expense, NLCP is immune. They have no debt maturities until May 2027.
As of January 21, 2026, the market is pricing NLCP with extreme caution.
Current Trading Metrics:
Share Price: ~$15.05.
Market Cap: ~$315 Million.
Annualized Dividend: $1.72.
Dividend Yield: 11.4%.
Price / AFFO (2025e): ~$15.05 / ($0.52 * 4) = ~7.2x.
Comparative Valuation:
Innovative Industrial Properties (IIPR): Trades at ~13x AFFO with a yield of ~7.5%.
Industrial REITs (e.g., Prologis): Trade at ~20x FFO.
The "OTC Discount": The valuation gap between NLCP (7.2x) and IIPR (13x) implies a nearly 50% discount applied to NLCP solely due to its exchange listing and smaller size. If NLCP were to uplist and re-rate to just 10x AFFO, the stock would trade at $20.80, representing ~38% upside from current levels.
Net Asset Value (NAV) Estimate: Conservatively estimating the liquidation value of the portfolio:
Real Estate Assets: $432M
Cash: $24M
Less Liabilities: ($10M)
Net Asset Value: ~$446M
Shares Outstanding: ~21M
NAV per Share: ~$21.23
Conclusion: The stock is trading at a ~30% discount to the book value of its assets. Investors are buying dollar bills for 70 cents.
The most immediate risk to NLCP's cash flow is the solvency of its tenants. The cannabis industry has faced a "Great Filtration" in 2024-2025, weeding out inefficient operators.
Case Study: AYR Wellness
The Issue: AYR Wellness, a major tenant, experienced liquidity crunches in Q3 2025, failing to make rent payments in August and September for two cultivation properties.
The Mitigation: NLCP utilized security deposits ($505k) to cover the shortfall. This protected the dividend in the short term.
The Outlook: AYR has entered into restructuring support agreements and received waivers on debt covenants.
Case Study: Revolutionary Clinics
The Issue: This tenant entered receivership in Massachusetts, leading to a vacancy at the Fitchburg facility.
The Impact: This vacancy creates a drag on earnings and tests management's ability to re-lease specialized assets. The Massachusetts market is highly saturated, making it a "buyer's market" for facilities.
The Lesson: This highlights the risk of "Asset Specificity." Unlike a generic warehouse, a grow facility cannot be easily repurposed for non-cannabis tenants without significant demolition costs.
The timeline for rescheduling is the single largest source of volatility.
The Event: The DEA hearing on rescheduling, scheduled for January 21, 2026, was postponed by the Administrative Law Judge (ALJ).
The Implication: This delay pushes the potential implementation of Schedule III—and the removal of 280E—deeper into 2026 or potentially 2027.
Market Reaction: The market hates uncertainty. Delays cause "fatigue selling" from retail investors who expected a quick resolution following the Trump EO.
Risk: If the rescheduling process is derailed entirely (e.g., by litigation from prohibitionist groups), the "Schedule III premium" built into the stock will evaporate, potentially sending shares back to the $12.00 range.
Interest Rates: As the Federal Reserve navigates the "soft landing" or "no landing" scenario in 2026, interest rates remain elevated compared to the 2010s. While NLCP has no debt, higher risk-free rates (10-year Treasury) make NLCP's 11% yield relatively less attractive. If Treasuries yield 5%, an 11% risky yield is less compelling than if Treasuries yielded 1%.
Inflation: Inflation works in NLCP's favor regarding asset value (replacement cost of building new facilities skyrockets), but it hurts tenants who face rising costs for labor, electricity, and fertilizer, squeezing their margins and ability to pay rent.
NLCP trades on the OTC. OTC markets are thinner, with lower trading volumes ($1M - $2M per day).
Liquidity Risk: Large sellers can crash the price easily.
Spread Risk: Bid-ask spreads can be wider.
Custody Risk: Some brokers may stop allowing purchases of cannabis-related stocks if the DOJ shifts its enforcement posture.
This forward-looking analysis models three potential paths for NLCP through 2031, weighting them by probability based on the current political and economic landscape.
Probability: 30%
Assumptions:
Rescheduling to Schedule III is finalized by Q4 2026.
280E is retroactively removed for 2026 tax year.
NLCP uplists to NASDAQ/NYSE in 2027.
Institutional capital floods the sector; NLCP issues equity at premium to NAV to double its portfolio size.
Dividend grows at 8% CAGR.
Valuation: Re-rates to 15x AFFO (parity with IIPR).
2030 Financials: AFFO/Share hits $3.00.
Projected Share Price: $45.00
Total Return: ~300% (Price + Dividends).
Probability: 50%
Assumptions:
Rescheduling drags on until 2027/2028 due to lawsuits.
No uplisting; NLCP remains OTC.
Tenants struggle but survive; occupancy stays ~95%.
Growth is limited to 2.5% rent escalators.
Dividend grows at 2% CAGR.
Valuation: Multiples stay compressed at 8x AFFO.
2030 Financials: AFFO/Share hits $2.30 (organic growth).
Projected Share Price: $18.40
Total Return: ~85% (Primarily driven by the 11% yield compounding).
Probability: 20%
Assumptions:
Rescheduling is rejected/withdrawn. DOJ increases enforcement.
AYR Wellness and another top tenant default, pushing vacancy to 20%.
Dividend is cut by 40% to preserve cash.
NAV erodes as facilities are sold at distress prices.
Valuation: Compresses to 5x distressed AFFO.
2030 Financials: AFFO/Share drops to $1.20.
Projected Share Price: $6.00
Total Return: -40% (Capital loss outweighs dividend income).
This section evaluates NLCP on critical qualitative metrics essential for REIT success. Scores are based on a 1-10 scale (10 being best-in-class).
Table 6.1: NLCP Qualitative Scorecard
| Category | Score | Analysis |
| Management Quality | 9/10 | CEO Anthony Coniglio has shown exceptional discipline. Refusing to grow for growth's sake during the bubble of 2021-2022 saved the company. Insider buying in late 2025 |
| Balance Sheet Health | 10/10 | With <2% leverage and $106M liquidity, the balance sheet is pristine. It is "bulletproof" against rate hikes. |
| Revenue Quality | 6/10 | While NNN leases are high quality, the underlying credit of the tenants (Cannabis MSOs) is speculative. The AYR Wellness issues drag this score down. |
| Asset Quality | 7/10 | Modern cultivation facilities are valuable, but the lack of alternative use (high asset specificity) is a structural risk compared to generic warehouses. |
| Dividend Safety | 8/10 | 82% payout ratio is healthy. The lack of debt service means AFFO is "true" cash available for distribution. |
| Regulatory Insulation | 2/10 | The company is highly exposed to political whims. A stroke of a pen can double the stock or halve it. |
| Growth Potential | 8/10 | Potential is high due to the small base ($390M market cap). It is easier to double a $390M portfolio than a $50B portfolio. |
| Weighted Average | 7.1/10 | Solid investment grade quality masked by regulatory risk. |
The Asymmetric Trade NewLake Capital Partners offers a rare asymmetry in the current market.
The Floor: The downside is buffered by the tangible value of the real estate ($21/share NAV) and the massive yield (11.4%). Even in a "muddle through" scenario, the income return is substantial.
The Ceiling: The upside is unconstrained. If regulatory reform hits, the re-rating could be violent and rapid, delivering multi-bagger returns.
Thesis Summary: We are at "Peak Pessimism" regarding the cannabis trade. The delays in rescheduling have flushed out the impatient capital. Investors entering now are buying a 12% cap rate portfolio with a fortress balance sheet at a 30% discount to replacement cost. The primary risk is not that the business fails, but that the waiting game for regulatory reform takes longer than the market's solvency patience.
Actionable Advice:
Accumulate on dips below $15.00.
Monitor the AYR Wellness restructuring news closely; this is the canary in the coal mine.
Watch the Federal Register for new dates regarding the DEA hearing.
Hold in a tax-advantaged account (IRA/Roth) to maximize the compounding of the high dividend, as REIT dividends are taxed as ordinary income.
Final Verdict: Buy.
In early January 2026, NLCP's daily chart printed a Golden Cross, where the 50-day Simple Moving Average (SMA) crossed above the 200-day SMA.
Significance: This is a classic long-term bullish signal. It indicates that the intermediate-term momentum (50-day) is now stronger than the long-term trend (200-day), often marking the end of a bear market phase.
Historical Context: The last time the sector saw such technical setups was prior to the 2021 run-up.
Current Price: ~$15.05.
200-Day Moving Average: ~$14.44.
Immediate Resistance: ~$15.50. The stock has struggled to break this level in recent weeks. A clean break above $15.50 on high volume would open the door to a test of the 52-week highs.
52-Week High: $17.15.
RSI (14): Currently reading ~42 (Neutral).
MACD: Showing a slight bearish divergence in the very short term (days), suggesting the stock may consolidate or pull back slightly to test the $14.50 support before moving higher.
Volume: Recent volume has been light
The Setup: The stock is compressing in a tight range between the 200-day MA ($14.44) and overhead resistance ($15.50).
The Trigger: News regarding a new DEA hearing date or positive earnings from a top tenant could trigger the breakout.
Prediction: Expect a retest of the $14.50 level. If it holds, the stock is technically primed for a run to $16.00. If $14.50 fails, the next support is $13.80. Given the Golden Cross, the bias is to the upside.
Chart Strategy: Buy limit orders placed at $14.65 offer an excellent risk/reward ratio, with a tight stop loss at $13.90 and a target of $16.50.
To fully appreciate the risk profile, we must dissect the tenant base beyond the top-line numbers.
Table 9.1: Top Tenant Exposure
Analysis: The portfolio follows a "Barbell Strategy."
Safe End: ~60% of the rent comes from Tier 1 MSOs (Curaleaf, Trulieve, Verano, Cresco) who are generating operational cash flow and are unlikely to default.
Risky End: ~20% comes from distressed or Tier 2 operators (AYR, Rev Clinics, private operators). This is where the yield comes from, but also the sleepless nights.
Mitigation: The Security Deposit application for AYR proves the system works.
Why is a building in Pennsylvania worth more than a building in California?
Pennsylvania: A highly restrictive limited-license state. Only a handful of grower-processor licenses exist. To sell cannabis in PA, you must grow it in one of these licensed facilities.
Result: The NLCP facility in PA is a monopoly asset. If the tenant leaves, the license is so valuable that a new operator will eagerly take over the lease to get the license.
California/Massachusetts: Unlimited or loose licensing. Over-supply of cultivation.
Result: If a tenant fails in MA (like Rev Clinics), finding a new tenant is hard because there are already too many growers. The "license value" is near zero.
NLCP Strategy: Management has explicitly pivoted away from unlimited markets and toward limited markets (like the recent expansion into Missouri and Connecticut). This is a crucial defensive moat.
WALT (Weighted Average Lease Term): The portfolio WALT is approximately 12.7 years.
Implication: This locks in the revenue stream through the next business cycle. Even if market rents drop, NLCP's tenants are contractually obligated to pay the higher existing rent for over a decade.
Most REITs rely on the "spread investing" model: borrow at 4%, buy at 6%, pocket the 2% spread.
The Problem: In 2024-2025, borrowing costs hit 6-7%. Buying at 6% cap rates became unprofitable. Transaction volume froze.
The NLCP Edge: Because cannabis is federally illegal, NLCP could never borrow cheaply anyway. They were forced to build a business model that worked with 100% equity.
Result: Now that debt is expensive for everyone, NLCP is on equal footing. They buy at 12-13% yields using equity. The spread is 12% (Yield) - 11% (Cost of Equity/Dividend) = 1% positive spread. It's tight, but positive.
Future Leverage: If rescheduling allows NLCP to borrow at 6%, they can leverage their 13% yielding portfolio to generate massive spread income. This is the "Leverage Latency" upside.
Triple-Net (NNN): As discussed, the tenant pays the bills. If property taxes soar (common in 2025), the tenant pays. If insurance premiums double (common in climate-risk areas), the tenant pays. NLCP's margin is protected.
Replacement Cost: Inflation has driven up the cost of steel, concrete, and labor. To build a new 50,000 sq ft indoor grow facility now costs ~$400/sq ft. NLCP likely bought theirs for ~$250-$300/sq ft years ago. This means their basis is below replacement cost—a key value investor metric.
Many small REITs are "externally managed," meaning an outside firm runs them and charges a fee based on Assets Under Management (AUM). This creates a conflict of interest: the manager wants to buy everything (good or bad) to increase fees.
NLCP is Internally Managed: The management team works for the shareholders. They are incentivized to grow per share value (AFFO/share), not just total size.
Evidence: In 2023-2024, when the stock price dropped, management stopped buying properties. An external manager would have kept buying to grow fees. This discipline preserved shareholder value and prevented dilution.
The purchase of ~10,000 shares by CEO Anthony Coniglio in late 2025
Signal: Executives rarely buy stock for income (they have salaries). They buy for capital appreciation. The CEO buying at $15.10 implies he sees the intrinsic value significantly higher (likely $20+).
The long-term risk (10+ years) for cannabis is that it becomes an agricultural commodity like corn or soybeans. If federal legalization allows interstate commerce, cultivation will move to mega-farms in the Midwest or outdoor grows in the South.
Threat: Expensive indoor facilities in the Northeast (NLCP's bread and butter) could become obsolete.
Counter-Argument: Premium cannabis ("Top Shelf") requires indoor climate control to prevent mold and ensure consistency. Just as we have cheap box wine (outdoor grapes) and expensive Napa wine (controlled vines), cannabis will bifurcate. NLCP is betting on the "Napa Valley" segment of the market.
The postponement of the DEA hearing reminds us that politics is non-linear. A new administration or a change in DOJ leadership could freeze rescheduling for another 4 years.
Scenario: If a staunch prohibitionist is appointed to key DOJ roles, the "Trump EO" could be ignored or slow-walked. This is the "Stroke of Pen" risk that can never be fully modeled.
Report compiled using primary source data from SEC filings, Investor Relations releases, and market data as of January 21, 2026.
View NewLake Capital Partners, Inc. (NLCP) stock page
Loading the interactive version of this report…